- Notification that Annual Report will be submitted late (NT 10-K)
April 01 2009 - 3:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one): [x] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q
[ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: December 31, 2008
[ ] Transition report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________________
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
IGENE BIOTECHNOLOGY, INC.
Full Name of Registrant
N/A
Form Name if Applicable
9110 Red Branch Road
Address of Principal Executive Office (Street and Number)
Columbia, Maryland 21045-2024
City, State and Zip Code
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reason described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense.
(b) The subject annual report, semi-annual report, transition report
on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
[x] day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date;
and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-
SAR, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed time period.
The Registrant encountered technical difficulties when attempting to
electronically file its annual report on Form 10-K for the year ended
December 31, 2008 on the afternoon of March 31, 2009. These technical
difficulties caused the report to be filed at 5:43 pm on March 31, 2009.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Edward J. Weisberger 410 997-2599
_____________________________ ___________ ____________________
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
|
of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter
period that the registrant was required to file such report(s) been
filed? If answer is no, identify report(s). Yes [x] No [ ]
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject
report or portion thereof? Yes [ ] No [x]
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
IGENE BIOTECHNOLOGY, INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
DATE: April 1, 2009 By: /s/ EDWARD J. WEISBERGER
_____________ ____________________________
EDWARD J. WEISBERGER
Chief Financial Officer
|
IGENE Biotechnology (CE) (USOTC:IGNE)
Historical Stock Chart
From Sep 2024 to Oct 2024
IGENE Biotechnology (CE) (USOTC:IGNE)
Historical Stock Chart
From Oct 2023 to Oct 2024